## **Information Disclosure Statement**

Box DD Commissioner for Patents Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.


This Information Disclosure Statement:

(a)	accompanies the new patent application submitted herewith.	37	CFR
§1.97(a	a).		

- (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) $\boxtimes$  as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

Page 2					•
	as is k rejecti either specif Depos Inform	ation filing date known to the use on or a notice the fee (\$180. ied in 37 CFR sit Account No	e or PCT national undersigned, prion of allowance, when 00) set forth in 3 §1.97(e), as che ure Statement is p	tion and more than thread stage date of entry filing to the mailing date of eichever occurs first, and 7 CFR §1.17(p) or a centre cked below. Authorizate amount of \$180.00 to controvided in the Transmit	ng but, as far either a final d is accompanied by rtification as ion to charge over the cost of this
	Trans No. 0 as spe	ance, whicheve mittal Letter su 7-1048 the fee ecified in 37 Cl dered as a pe	er occurred first, about the control of the control	of either a final rejection and is accompanied by in duplicate) to charge th in 37 CFR §1.17(I)(1) checked below. This dog consideration of the	authorization (in the Deposit Account) and a certification ocument is to be
[If either of b	oxes (	d) or (e) is ch	ecked above, th	e following "certificat	ion" under 37 CFR
§1.97(e) may	need	to be complet	ted.] The unders	igned certifies that:	
	count	ment was cited erpart foreign	d in a communica	ained in the Information tion mailed from a forei ore than three months p t.	gn patent office in a
	foreig reaso more	cited in a comn in application on able inquiry,	nunication mailed or, to the knowled was known to an	ned in this Information I from a foreign patent of ge of the undersigned a y individual designated filing of this Information	office in a counterpart after making in 37 CFR §1.56(c)
Those patent	:(s) or p	oublication(s) w	vhich are marked	with an asterisk (*) on t	the attached Form
PTO-1449 ar	e not s	upplied becaus	se they were prev	viously cited by or subm	itted to the Office in
a prior applic	ation, S	Serial No.	filed	, and relied upo	n in this application
for an earlier	filing d	ate under 35 L	JSC 120.		
A concise ex	planatio	on of relevance	e of the items list	ed on PTO-1449 is:	
	$\boxtimes$	not given			
		given for ea	ch listed item		

Serial No. 10/022,097



The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: May 15, 2001

H. Thomas Anderton, Jr. Registration No. 40,895

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7544 Fax: 650 845-6504

Examiner's	Document				Sub-	FFING 80
Initial	Number	Date	Name	Class	Class	_Date
	4,601,978	07/22/86	Karin	435	68	<b>1</b> /24/8
	5,061,620	10/29/91	Tsukamoto et al.	435	7.21	<b>30/90</b>
***************************************	5,961,973	10/05/99	Crea	424	133.1	नी/13/95
	5,011,686	04/30/91	Pang	424	94.1	11/15/89
	5,683,888	11/04/97	Campbell	435	8	07/05/94
	4,458,066	07/03/84	Caruthers et al.	536	27	03/23/81
	5,750,356	06/12/98	Spack et al.	435	7.24	06/31/96
	4,675,187	06/23/87	Konishi et al.	424	117	08/23/85
- <del></del> -	4,975,278	12/04/90	Senter et al.	424	94.3	06/29/88
	6,261,535 B1	07/17/01	Thorpe et al.	424	1.49	12/08/98
	6,025,485	02/15/00	Kamb et al.	536	25.32	11/06/97
	5,677,136	10/14/97	Simmons et al.	435	7.24	11/14/94
	4,522,811	06/11/85	Eppstein et al.	514	2	07/08/82
	4,666,848	05/19/87	Gelfand et al.	435	253	08/31/84
,,,,,,	5,750,397	01/12/98	Tsukamoto et al	435	372	06/06/95
	5,472,855	12/05/95	Carter et al.	435	68.1	09/22/94
	5,371,190	12/06/94	Carter et al.	530	350	07/12/93
	5,711,944	01/27/98	Gilbert et al.	424	85.7	11/10/94
33.4.	5,766,883	06/16/98	Ballance et al.	435	69.7	11/17/93
	5,843,440	12/01/98	Pouletty et al.	424	133.1	08/14/96
	4,711,845	12/08/87	Gelfand et al.	435	68	12/24/84
<del> </del>	4,419,446	12/06/83	Howley et al.	435	68	12/31/80
	4,399,216	08/16/83	Axel et al.	435	6	02/25/80

## FOREIGN PATENT DOCUMENTS

Examiner's	Document					Sub-	Translation
Initials	Number	Date	Country		Class	Class	Yes/No
	WO 00/24782	05/04/00	PCT - Note: 435 have not been in	pages of sequence listings cluded.			
	WO 99/53038	10/21/99	PCT	6			
<del>.</del>	WO 99/61916	12/02/99	PCT	,			
	0 196 864 A2	03/25/86	РСТ				
Examiner				Date Considered			-

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

PTO-1449

Attorney Docket No.: GC-714	PE	Serial No.: 10/022,097	
Applicant: Schellenberger, Volker	100		RECEIVED
Filing Date: December 13, 2001	MAY 2 0 2002	Group: Unassigned	2-2 2002
Page 2 of 5	A. C.	Date of this Submission: May 15, 2002	MAI 2, 12 East
	Ce at		- CLI CENTER 1600/2900

Page 2 of 5	Date of this Submission: May 15, 2002							
	OTHER DOCUMENTS  TECH CENTER 1600/290							
Examiner's								
Initials	Author, Title, Date, Pertinent Pages, etc.							
	Altschul et al., "Basic Local Alignment Search Tool," J. of Molecular Biology, Vol. 215, pp. 403-410, 1990							
	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Res., Vol. 25, No. 17, pp. 3389-3402, 1997							
<del></del>	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science, Vol. 279, pp. 377-380, Jan. 1998							
	Ausubel et al., Eds., Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York, pp. 2.10.1-16, 1989							
	Axe, D., "Extreme Functional Sensitivity to Conservative Amino Acid Changes on Enzyme Exteriors, J. Mol. Biol., Vol. 301, pp. 585-595, 2000							
	Bagshawe et al., "Developments with targeted enzymes in cancer therapy," Current Opinion in Immunology, Vol. 11, pp. 579-83, 1999							
	Barbas et al., Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001 Listed but not sent in.							
	Beaucage et al., "Deoxynucleoside Phosphoramidites-A new Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Lett., Vol. 22, pp. 1859-1862, 1981							
	Bekkers et al., "Targeting of Porcine Pancreatic Phospholipase A <sub>2</sub> to Human Platelets: Introduction of an RGD Sequence by Genetic Engineering," <i>Throm. Haemost</i> , Vol. 74, No. 4, pp. 1138-1144, 1995							
	Benito et al, "Insertion of a 27 amino acid viral peptide in different zones of Escherichia coli β-galactosidase: Effect on the enzyme activity," FEMS Microbiology Letters, Vol. 123, pp. 107-112, 1994							
	Berger, S., "Expanding the Potential of Restriction Endonucleases: Use of Hapaxoterministic Enzymes," Analytical Biochemistry, Vol. 222, pp. 1-8, 1994							
•	Berger, S. et al, "Phoenix Mutagenesis: One-Step Reassembly of Multiply Cleaved Plasmids with Mixtures of Mutant and Wild-Type Fragments," Analytical Biochemistry, Vol. 214, pp. 571-579, 1993							
	Biondi et al., "Random insertion of GFP into the cAMP-dependent protein kinase regulatory subunit from Dictyostelium discoideum, Nucleic Acids Research, Vol. 26, No. 21, pp. 4946-4952, 1998							
· <del>-</del>	Bolivar et al., " Construction and Characterization of New Cloning Vehicles, " Gene, Vol. 2, pp. 95-113, 1977							
•	Brennan et al.,"A molecular sensor system based on genetically engineering alkaline phosphatase," Proc. Natl. Acad. Sci., Vol. 92, pp. 5783-5787, 1995							
	Broach, J.R., "Construction of High Copy Yeast Vectors using 2-µm Circle Sequences," Meth. In Enzymology, Vol. 101, pp. 307-324, 1983							
	Brown et al., "Chemical Synthesis and Cloning of a Tyrosine tRNA Gene," Meth. Enzymol., Vol. 68, pp.109-151, 1979							
····	Carter et al., " Engineering Enzyme Specificity by 'Substrate-Assisted Catalysis," Science, Vol. 237, pp. 237-394, 1987							
	Chaga et al., "Engineering of a metal coordinating site into human glutathione transferase M1-1 based on immobilized metal ion affinity chromatography of homologous rat enzymes," <i>Protein Engineering</i> , Vol. 7, No. 9, pp. 1115-1119, 1994							
	Chari, R., "Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy," Adv. Drug. Deliver. Rev., Vol. 31, pp. 89-104, 1998							
	Christofidou-Solomidou et al., "Immunotargeting of glucosooxidase to endothelium in vivo causes oxidative vascular injury in the lungs," Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 278, pp. L794-L805, 2000							
	Clackson et al., "Making antibody fragments using phage display libraries," Nature, Vol. 352, pp. 624-28, 1991							
	Clarke et al., "Selection Procedure for isolation of Centromere DNAs from Saccharomyces cerevisiae," Meth.In Enz., Vol. 101, pp. 300-307, 1983							
	Clewell et al., "Supercoiled Circular DNA-Protein Complex in Escherichia Coli: Purification and Induced Conversion to an Open Circular DNA Form," Proc. Natl. Acad. Sci. USA, Vol. 62, pp. 1159-1166, 1969							
	Clewell, J., "Nature of Col E <sub>1</sub> Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol," Bacteriol., Vol. 110, pp. 667-675, 1972							
	Cohen et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of <i>Escherichia coli</i> by R-Factor DNA," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 69, pp. 2110-2114, 1972  Colas et al., "Targeted modification and transportation of cellular proteins," <i>PNAS</i> , vol. 97, No. 25, pp. 13720-13725, 2000							
	Collinet et al., "Functionally Accepted Insertions of Proteins within Protein Domains," J. of Biological Chemistry, Vol. 275, No. 23, pp. 17428-17433, 2000							
	Corey et al., "Trypsin Specificity Increased through Substrate-Assisted Catalysis," <i>Biochemistry</i> , Vol. 34, pp. 11521-27, 1995							
	Cruz and Patterson, Eds., Tissue Culture, Academic Press, 1973 Listed but not sent in.							
Examiner	Date Considered							
	Date Vollsidered							

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Attorney Docket No.: GC-714	OF	Serial No.: 10/022,097
Applicant: Schellenberger, Volker	(3)	
Filing Date: December 13, 2001	MAY 2 0 2002	Group: Unassigned
Page 3 of 5	PAT	Date of this Submission: May 15, 2002
	The state of the s	DECLIVED

et al., "Substrate-assisted nes et al., "A peptide-doxontigen in vivo," Nat. Med., Vet al., "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tec al., "Clinical applications of al., "Complete nucleotide sec al., "Targeted Toxins," Clinical, "VEGF couples hypertromal, "VEGF couples hypertromal, "VEGF couples hypertromal, "Synthesis of human for al., "Synthesis of human for al., "Conjugates of Oligonucle, 165-187, 1990 det al., "Poly(ethylene glycology, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	e specificity tailor de catalysis: Mole orubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEBS of angiogenic groequence of SV40 m. Cancer Res., trophic cartilage fibroblast interference of Conjugated mutagenesis: raties To Two Determinence Two De	lecular basis and biolog' activated by prostate pp.1248-1252, 2000 ping and DNA Sequented random polypeptide as Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 2010 Ping and Prodrugs:  Modified Oligonucleotic Drugs and Prodrugs:	therapeutic properties by assisted catalysis and poical significance," Protested especific antigen selections," J. Mol. Appl. Gen., Vol. 1999  Inhibitors," Nat. Med., Vol. 273, pp. 113-120, 1978  2000  In and angiogenesis due Acids Res., Vol. 8, pp. 4  es: A Review of Their State A Comprehensive Review	vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation," Nature Medicine,
itle, Date, Pertinent Pages al., "Enhancement of tumor I., Vol.18, pp. 1185-1190, 20 a et al., "Elastase substrate a et al., "Substrate-assisted nes et al., "A peptide-doxor ntigen in vivo," Nat. Med., Vol. et al., "Nopaline synthase: T "Screening of conformation "Insertional gene fusion tec al., "Clinical applications of ., " Complete nucleotide sec al., "Targeted Toxins," Clin al., "VEGF couples hypertr . 6, pp. 623-628, 1999 et al., "Synthesis of human for .J., "Conjugates of Oligonuc pp. 165-187, 1990 d et al., "Poly(ethylene glyc d et al., "Poly(ethylene glyc l., "Pentapeptide scanning r o. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	e specificity tailor de catalysis: Mole orubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEBS of angiogenic groequence of SV40 m. Cancer Res., trophic cartilage fibroblast interference of Conjugated mutagenesis: raties To Two Determinence Two De	lecular basis and biolog' activated by prostate pp.1248-1252, 2000 ping and DNA Sequented random polypeptide as Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 2010 Ping and Prodrugs:  Modified Oligonucleotic Drugs and Prodrugs:	-assisted catalysis and gical significance," Protest-specific antigen selections," J. Mol. Appl. Gen., Volibraries displayed on a 1-4, 1999 • nhibitors," Nat. Med., Vol. 73, pp.113-120, 1978 2000 on and angiogenesis durant Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Review	by targeted deliver to a hipoperioase N (CD13)," Nat. I phage display, " Protein Eng., Vol. 12, No. 11, pp. 981  tein Science, Vol. 9, pp.1-9, 2000  tively kills prostate tumor cells positive for prostate-  , Vol. 1, pp. 561-573, 1982  a protein scaffold," Cell. Mol. Life Sci., Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine,  4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.  riew," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
al., "Enhancement of tumor I., Vol.18, pp. 1185-1190, 20 a et al., "Elastase substrate a et al., "Substrate-assisted nes et al., "A peptide-doxor tigen in vivo," Nat. Med., Vol. 18, "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tec al., "Clinical applications of al., "Clinical applications of al., "Complete nucleotide sec al., "Targeted Toxins," Clinical, "VEGF couples hypertropedal, "Synthesis of human for pp. 6, pp. 623-628, 1999  et al., "Synthesis of Oligonuc op. 165-187, 1990 det al., "Poly(ethylene glycology, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	e specificity tailor d catalysis: Mole orubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEB: of angiogenic grown. Cancer Res., trophic cartilage fibroblast interference of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated color of SV40 colo	lecular basis and biolog' activated by prostate pp.1248-1252, 2000 ping and DNA Sequented random polypeptide as Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 2010 Ping and Prodrugs:  Modified Oligonucleotic Drugs and Prodrugs:	-assisted catalysis and gical significance," Protest-specific antigen selections," J. Mol. Appl. Gen., Volibraries displayed on a 1-4, 1999 • nhibitors," Nat. Med., Vol. 73, pp.113-120, 1978 2000 on and angiogenesis durant Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Review	by targeted deliver to a hipoperioase N (CD13)," Nat. I phage display, " Protein Eng., Vol. 12, No. 11, pp. 981  tein Science, Vol. 9, pp.1-9, 2000  tively kills prostate tumor cells positive for prostate-  , Vol. 1, pp. 561-573, 1982  a protein scaffold," Cell. Mol. Life Sci., Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine,  4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.  riew," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
et al., "Substrate-assisted nes et al., "A peptide-doxontigen in vivo," Nat. Med., Vet al., "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tec al., "Clinical applications of al., "Complete nucleotide sec al., "Targeted Toxins," Clinical, "VEGF couples hypertromal, "VEGF couples hypertromal, "VEGF couples hypertromal, "Synthesis of human for al., "Synthesis of human for al., "Conjugates of Oligonucle, 165-187, 1990 det al., "Poly(ethylene glycology, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	d catalysis: Mole prubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEB: of angiogenic grown. Cancer Res., trophic cartilage fibroblast interference of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated c	lecular basis and biolog' activated by prostate pp.1248-1252, 2000 ping and DNA Sequented random polypeptide as Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 2010 Ping and Prodrugs:  Modified Oligonucleotic Drugs and Prodrugs:	-assisted catalysis and gical significance," Protest-specific antigen selections," J. Mol. Appl. Gen., Volibraries displayed on a 1-4, 1999 • nhibitors," Nat. Med., Vol. 73, pp.113-120, 1978 2000 on and angiogenesis durant Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Review	tein Science, Vol. 9, pp.1-9, 2000  tively kills prostate tumor cells positive for prostate-  , Vol. 1, pp. 561-573, 1982  a protein scaffold," Cell. Mol. Life Sci., Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol. 1999  view," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
et al., "Substrate-assisted nes et al., "A peptide-doxontigen in vivo," Nat. Med., Vet al., "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tec al., "Clinical applications of al., "Complete nucleotide sec al., "Targeted Toxins," Clinical, "VEGF couples hypertromal, "VEGF couples hypertromal, "VEGF couples hypertromal, "Synthesis of human for al., "Synthesis of human for al., "Conjugates of Oligonucle, 165-187, 1990 det al., "Poly(ethylene glycology, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	d catalysis: Mole prubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEB: of angiogenic grown. Cancer Res., trophic cartilage fibroblast interference of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated mutagenesis: raties To Two Determinence of SV40 col) Conjugated c	lecular basis and biolog' activated by prostate pp.1248-1252, 2000 ping and DNA Sequented random polypeptide as Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 2010 Ping and Prodrugs:  Modified Oligonucleotic Drugs and Prodrugs:	-assisted catalysis and gical significance," Protest-specific antigen selections," J. Mol. Appl. Gen., Volibraries displayed on a 1-4, 1999 • nhibitors," Nat. Med., Vol. 73, pp.113-120, 1978 2000 on and angiogenesis durant Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Review	tein Science, Vol. 9, pp.1-9, 2000  tively kills prostate tumor cells positive for prostate-  , Vol. 1, pp. 561-573, 1982  a protein scaffold," Cell. Mol. Life Sci., Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol. 1999  view," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
nes et al., "A peptide-doxontigen in vivo," Nat. Med., Vet al., "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tec al., "Clinical applications of al., "Complete nucleotide sec al., "Targeted Toxins," Clinical, "VEGF couples hypertromal, "VEGF couples hypertromal, "Synthesis of human for p. 165-187, 1990 det al., "Poly(ethylene glycology, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	rubicin 'prodrug /ol. 6, No. 11, pp Transcript Mapp nally constrained chnology," FEBS of angiogenic gro equence of SV40 n. Cancer Res., trophic cartilage fibroblast interfe ucleotides and M col) Conjugated mutagenesis: ra	g' activated by prostate pp.1248-1252, 2000 ping and DNA Sequent of random polypeptide  S Letters, Vol. 457, pp. owth factors and their O DNA, " Nature, Vol. 3 Vol. 6, pp. 326-334, 3 e remodeling, ossification of the production	e-specific antigen selection, Value of J. Mol. Appl. Gen., Value of Sen., Vol. 8, pp. 4 es: A Review of Their Sen. A Comprehensive Review	ctively kills prostate tumor cells positive for prostate-  Nol. 1, pp. 561-573, 1982  a protein scaffold," Cell. Mol. Life Sci., Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine,  4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.  view," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
et al., "Nopaline synthase: To "Screening of conformation of "Insertional gene fusion tectal., "Clinical applications of complete nucleotide sectal., "Complete nucleotide sectal., "Targeted Toxins," Clinical., "VEGF couples hypertromal., "VEGF couples hypertromal., "Synthesis of human for the couples of Oligonucle couples al., "Synthesis of human for the couples of Oligonucle couples al., "Poly(ethylene glycological, "Pentapeptide scanning roop, pp. 1866-1867, 1997 et al., "Monoclonal Antibodical couples and the couples al., "Monoclonal Antibodical couples al., "Monoclonal couples al., "Monoc	Transcript Mapp Transcript Mapp nally constrained chnology," FEBS of angiogenic gro equence of SV40 n. Cancer Res., trophic cartilage fibroblast interfe ucleotides and M col) Conjugated mutagenesis: ra fies To Two Det	ping and DNA Sequented random polypeptide  S Letters, Vol. 457, pp  owth factors and their  O DNA, " Nature, Vol. 2  Vol. 6, pp. 326-334, 2  e remodeling, ossification  eron by E. Coli," Nuc.  Modified Oligonucleotic  Drugs and Prodrugs:	ce," J. Mol. Appl. Gen., Vol. 1-4, 1999  nhibitors," Nat. Med., Vol. 73, pp. 113-120, 1978  con and angiogenesis due  Acids Res., Vol. 8, pp. 4 es: A Review of Their S  A Comprehensive Revie	Vol. 1, pp. 561-573, 1982  a protein scaffold," <i>Cell. Mol. Life Sci.</i> , Vol. 54, pp. 394-  Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " <i>Nature Medicine</i> , 4057-4075, 1980  Synthesis and Properties," <i>Bioconjugate Chemistry</i> , Vol. 1999  View," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , Vol. 17, pp.101
"Screening of conformation "Insertional gene fusion tec al., "Clinical applications of ., " Complete nucleotide sec al., "Targeted Toxins," Clin al., "VEGF couples hypertr . 6, pp. 623-628, 1999  et al., "Synthesis of human fi .J., "Conjugates of Oligonuc op. 165-187, 1990 d et al., "Poly(ethylene glyc l., "Pentapeptide scanning r o. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	Transcript Mappinally constrained chnology," FEBS of angiogenic group equence of SV40 m. Cancer Res., trophic cartilage fibroblast interference and Mappinal Collinguity Colli	ping and DNA Sequented random polypeptide  S Letters, Vol. 457, pp  owth factors and their  O DNA, " Nature, Vol. 2  Vol. 6, pp. 326-334, 2  e remodeling, ossification  eron by E. Coli," Nuc.  Modified Oligonucleotic  Drugs and Prodrugs:	hibraries displayed on a  1-4, 1999  nhibitors," Nat. Med., V  73, pp.113-120, 1978  2000  on and angiogenesis du  Acids Res., Vol. 8, pp. 4  es: A Review of Their S  A Comprehensive Revie	vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol. riew," Crit. Rev. Ther. Drug Carrier Syst., Vol. 17, pp.101
"Insertional gene fusion tec al., "Clinical applications of ., " Complete nucleotide sec al., "Targeted Toxins," Clin al., " VEGF couples hypertr . 6, pp. 623-628, 1999 et al., "Synthesis of human for .J., "Conjugates of Oligonuc op. 165-187, 1990 d et al., "Poly(ethylene glyc d., "Pentapeptide scanning ro. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	chnology," FEBS of angiogenic gro equence of SV40 on. Cancer Res., trophic cartilage fibroblast interfe ucleotides and M col) Conjugated mutagenesis: ra	owth factors and their O DNA, " Nature, Vol. : Vol. 6, pp. 326-334, 2 remodeling, ossification by E. Coli," Nuc. Modified Oligonucleotic Drugs and Prodrugs:	nhibitors," Nat. Med., V 273, pp.113-120, 1978 2000 on and angiogenesis du Acids Res., Vol. 8, pp. 4 es: A Review of Their S	Vol. 5, No. 12, pp. 1359-1364, 1999  uring endochondral bone formation, " Nature Medicine,  4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.
"Insertional gene fusion tecal., "Clinical applications of ., " Complete nucleotide secal., "Targeted Toxins," Clinical., "VEGF couples hypertr. 6, pp. 623-628, 1999  et al., "Synthesis of human for the secand period of the secand period period of the secand period of the secand period of the secand period of the secand period period of the secand period of the se	of angiogenic group of angiogenic group.  In . Cancer Res.,  trophic cartilage  fibroblast interference and Maccol) Conjugated  mutagenesis: radies To Two Determine the control of the co	owth factors and their O DNA, " Nature, Vol. 3. Vol. 6, pp. 326-334, 2. remodeling, ossification by E. Coli," Nuc. Modified Oligonucleotic Drugs and Prodrugs:	nhibitors," Nat. Med., V 273, pp.113-120, 1978 2000 on and angiogenesis du Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Revie	uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.
al., "Targeted Toxins," Clinal., "VEGF couples hypertr. 6, pp. 623-628, 1999  et al., "Synthesis of human for the couples of Oligonucop. 165-187, 1990 det al., "Pentapeptide scanning ro. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	requence of SV40  n. Cancer Res.,  trophic cartilage  fibroblast interference and Maccol) Conjugated  mutagenesis: raties To Two Determines	O DNA, " Nature, Vol. 2 Vol. 6, pp. 326-334, 2 e remodeling, ossification eron by E. Coli," Nuc. Modified Oligonucleotic d Drugs and Prodrugs:	273, pp.113-120, 1978 2000 on and angiogenesis du  Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Revie	uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980  Synthesis and Properties," Bioconjugate Chemistry, Vol.
al., "Targeted Toxins," Clin al., "VEGF couples hypertr. 6, pp. 623-628, 1999  et al., "Synthesis of human fr. J., "Conjugates of Oligonucop. 165-187, 1990 d et al., "Poly(ethylene glycol., "Pentapeptide scanning ro. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	n. Cancer Res., trophic cartilage fibroblast interfe ucleotides and M col) Conjugated mutagenesis: ra	Vol. 6, pp. 326-334, 2 remodeling, ossification by E. Coli," Nuc. Modified Oligonucleotical Drugs and Prodrugs:	2000  On and angiogenesis due  Acids Res., Vol. 8, pp. 4  es: A Review of Their S  A Comprehensive Revie	uring endochondral bone formation, " Nature Medicine, 4057-4075, 1980 Synthesis and Properties," Bioconjugate Chemistry, Vol.
al., "VEGF couples hypertr. 6, pp. 623-628, 1999  et al., "Synthesis of human for the star of Oligonuc op. 165-187, 1990  d et al., "Poly(ethylene glycol., "Pentapeptide scanning ro. 9, pp. 1866-1867, 1997  et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	fibroblast interferences  col) Conjugated  mutagenesis: radies To Two Determinences	e remodeling, ossification of the remodeling of	Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Revie	4057-4075, 1980 Synthesis and Properties," <i>Bioconjugate Chemistry</i> , Vol. riew," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , Vol. 17, pp.101
et al., "Synthesis of human for al., "Synthesis of human for al., "Conjugates of Oligonuclop. 165-187, 1990 det al., "Poly(ethylene glycol., "Pentapeptide scanning ro. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	fibroblast interference of the	eron by E. Coli," Nuc. Modified Oligonucleotic Drugs and Prodrugs:	Acids Res., Vol. 8, pp. 4 es: A Review of Their S A Comprehensive Revie	4057-4075, 1980 Synthesis and Properties," <i>Bioconjugate Chemistry</i> , Vol. riew," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , Vol. 17, pp.101
J., "Conjugates of Oligonuc op. 165-187, 1990 d et al., "Poly(ethylene glyc I., "Pentapeptide scanning r o. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	col) Conjugated mutagenesis: ra	Modified Oligonucleotic	es: A Review of Their S	Synthesis and Properties," Bioconjugate Chemistry, Vol.
J., "Conjugates of Oligonuc op. 165-187, 1990 d et al., "Poly(ethylene glyc I., "Pentapeptide scanning r o. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	col) Conjugated mutagenesis: ra	Modified Oligonucleotic	es: A Review of Their S	Synthesis and Properties," Bioconjugate Chemistry, Vol.
I., "Pentapeptide scanning roo. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	mutagenesis: ra		À	
o. 9, pp. 1866-1867, 1997 et al., "Monoclonal Antibodi 127 (No. 1), pp. 157-160, 1	lies To Two Det	andom insertion of a v	ariable five amino acid c	cassette in a target protein," Nucleic Acids Researcn,
127 (No. 1), pp. 157-160, 1		2/11/200		
ot al "Alkalina Phoennas		•		nergistically In Complement-Dependent Cytotoxicity," J.
			· · · · · · · · · · · · · · · · · · ·	nant Mirror Studies, J. Mol. Biol., Vol. 266, pp. 621-632,
., "Cooperation of Glycolytic	·			•
lycerate Kinase," Biochemis	istry, Vol. 17, pp	p. 4900-4907, 1978		ase, Glyceraldehyde-3-phosphate Dehydrogenase, and
3, 1979				
•				
ransport of Molecules in th	ne Tumor Inters	titium: A Review," Car	cer Res., Vol. 47, pp. 30	3039-3051, 1987
., "Epitope Tagging," Annu	J. Rev. Genet., \	Vol. 32, pp. 601-618,	998	
., Vol.18, No. 17, pp. 5315-	-5316, 1990			
Kerr et al., "Development and Activities of a New Melphalan Prodrug designed for Tumor-Selective Activation," <i>Bioconjugate Chemistry</i> , Vol. 9, pp. 25 59, 1998				
Kerr et al., "Application of Monoclonal antibodies against Cytosine Deaminase for the in Vivo Clearance of a Cytosine Deaminase Immunoconjugate,"				
Bioconjugate Chemistry, Vol. 4, pp. 353-357,1993  Legendre et al., " Engineering a regulatable enzyme for homogeneous immunoassays, " Natl. Biotechnol., Vol. 17, pp. 67-72, 1999				
		·		
•	nts, North Amer	rican Edition, 1983, Mo	Cutcheon Division of M	AC Publishing co., 175 Rock Road, Glen Rock, N.J.
		Date	Considered	
I all second	al., "High-Frequency transform, 1979 J., "Recombinant antibody form of the Property of Molecules in the Al., "Epitope Tagging," Annual al., "Construction of vectors, Vol.18, No. 17, pp. 5315-1, "Development and Activition, "Application of Monoclonal atte Chemistry, Vol. 4, pp. 3 et al., "Engineering a regulate al., "Substrate Specificity tal., "Sequencing End-Laber	al., "High-Frequency transformation of years 3, 1979 J., "Recombinant antibody fragments," Currol Transport of Molecules in the Tumor Intersel., "Epitope Tagging," Annu. Rev. Genet., al., "Construction of vectors with the p15a s., Vol.18, No. 17, pp. 5315-5316, 1990 J., "Development and Activities of a New Medical Chemistry, Vol. 4, pp. 353-357,1993 J. et al., "Engineering a regulatable enzyment al., "Substrate Specificity of Penicillin Small, "Sequencing End-Labeled DNA with Engineering En	al., "High-Frequency transformation of yeast by plasmids containing 3, 1979  J., "Recombinant antibody fragments," <i>Curr. Opin. Biotechnol.</i> , Vol. Transport of Molecules in the Tumor Interstitium: A Review," <i>Cantal.</i> , "Epitope Tagging," <i>Annu. Rev. Genet.</i> , Vol. 32, pp. 601-618, 1 al., "Construction of vectors with the p15a replicon, kanamycin rest, Vol. 18, No. 17, pp. 5315-5316, 1990  " "Development and Activities of a New Melphalan Prodrug design," "Application of Monoclonal antibodies against Cytosine Deaming atte Chemistry, Vol. 4, pp. 353-357,1993  et al., "Engineering a regulatable enzyme for homogeneous immediate." "Engineering a regulatable enzyme for homogeneous immediate." "Substrate Specificity of Penicillin Smidase From E. coli," Bit al., "Sequencing End-Labeled DNA with Base-Specific Chemical con's Emulsifiers & Detergents, North American Edition, 1983, Mcbut not sent in.	Transport of Molecules in the Tumor Interstitium: A Review," Cancer Res., Vol. 47, pp. 395-403, "Epitope Tagging," Annu. Rev. Genet., Vol. 32, pp. 601-618, 1998 al., "Construction of vectors with the p15a replicon, kanamycin resistance, inducible lacts, Vol.18, No. 17, pp. 5315-5316, 1990, "Development and Activities of a New Melphalan Prodrug designed for Tumor-Selective," "Application of Monoclonal antibodies against Cytosine Deaminase for the in Vivo Clearate Chemistry, Vol. 4, pp. 353-357,1993 et al., "Engineering a regulatable enzyme for homogeneous immunoassays," Natl. Bid et al., "Substrate Specificity of Penicillin Smidase From E. coli," Biochim. Biophys. Acta., al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages, Methods in the Colinary of Monoclonal antibodies against Cytosine Deaminase for the in Vivo Clearate Chemistry, Vol. 4, pp. 353-357,1993 et al., "Engineering a regulatable enzyme for homogeneous immunoassays," Natl. Bid al., "Substrate Specificity of Penicillin Smidase From E. coli," Biochim. Biophys. Acta., al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages, Methods in Sequencing End-Labeled DNA with American Edition, 1983, McCutcheon Division of Nature Colonary and Colonary a

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

PTO-1449

Attorney Docket No.: GC-714	PE	Serial No.: 10/022,097	
Applicant: Schellenberger, Volker	()		
Filing Date: December 13, 2001	MAY 2 0 2002	Group: Unassigned	DECENTED
Page 4 of 5	PATT	Date of this Submission: May 15, 2002	RECEIVED
	TO ADEMADY OTH	FR DOCUMENTS	MAY 2 2 2002

·····	OTHER DOC	CUMENTS MAY 2 2 2002					
Examiner's		TECH CENTER 1600/2900					
Initials	Author, Title, Date, Pertinent Pages, etc.	1 LOH OLIVIER 1000/2900					
	Melton & Knox, Enzyme-Prodrug Strategies for Cancer Therapies	s, Kluwer Academic/Plentum Publishers, N.Y., 1999 Listed but not sent in.					
	Messing et al., "A system for shotgun DNA sequencing," Nuc. Aci	ds Res., Vol. 9, pp. 309-321, 1981					
	Meyerhans et al., "DNA recombination during PCR," Nucleic Acid	s Res., Vol. 18, No. 7, pp.1687-1691, 1990					
	Miller et al., "An Insect Baculovirus Host-Vector System for High- Plenum Publishing, Vol. 8, pp. 227-97	Level Expression of Foreign Genes," Genetic Engineering, 1986, Setlow et al., Eds.,					
	Napolitano et al., "Glubodies: randomized libraries of glutathione	transferase enzymes," Chem. Biol., Vol. 3, pp. 359-367, 1996					
	Narang et al., "Improved Phosphotriester Method for the Synthesis of Gene Fragments," Meth. In Enzymol., Vol. 68, pp. 90-99, 1979						
	Niculescu-Duvaz et al., "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)," Anticancer Drug Des., Vol. 14, p						
	517-538, 1999  Niculescu-Duvaz et al., "Antibody-directed enzyme prodrug therapy (ADEPT): a review," Adv. Drug Del. Rev., Vol. 26, pp. 151-172, 1997						
	Norman et al., "Genetic Selection of peptide Inhibitors of Biological Pathways," Science, Vol. 285, pp. 591-595, 1999						
	Pantoliano et al., "The Engineering of Binding Affinity at Metal Ion Binding Sites for the Stabilization of Proteins," Biochemistry Vol. 27, pp. 8311-						
	1988 Philpott et al., "Selective Cytotoxicity of Hapten-Substituted Cells With An Antibody-Enzyme Conjugate," J. Immunol., Vol. 111, No. 3, pp. 921-929, 1973						
	Roberts et al., "Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors, Gene, Vol. 121, pp. 9-15, 1992						
·	Rubinstein et al., "Homogeneous Enzyme Immunoassay. A New Immunochemical Technique," Biochem. Biophys. Res. Commun., Vol. 47, pp. 846-851,						
	1972 Sala-Newby G.B. et al., Targeted Bioluminescent Indicators in LivingCells, 2000, Dept. of Medical Biochemistry, Univ. of Wales, College of Medicine,						
	Cardiff, United Kingdom Listed but not sent in.  Sambrook et al, Eds. Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, pp. 9.47-57, and Chapter 15.51, 1989						
	Sanger et al., "DNA sequencing with chain-terminating inhibitors," Proc. Natl. Acad. Sci. USA, Vol. 74, No. 12, pp. 5463-5467, 1977						
	Serpersu et al., "Kinetic and Magnetic Resonance Studies of Activ	ve Site Mutants of Staphylococcal Nuclease: Factors Contributing to Catalysis,"					
	Biochemistry, Vol. 26, pp. 1289-1300, 1987  Shaw et al., "A general method for the transfer of cloned genes to plant cells," Gene, Vol. 23, pp. 315-330, 1983						
	Sherwood, R., "Advanced drug delivery reviews: enzyme prodrug therapy," Advanced Drug. Del. Rev., Vol. 22, pp. 269-288, 1996						
		tes promoters for lysogenic development, Nature, Vol. 292, pp. 128-132 1981					
		Fv-β-Lactamase, a Single-Chain Antibody Fusion Protein for Anticancer Prodrug					
	Activation," Bioconjug. Chem., Vol. 8, pp. 510-519, 1997  Smith et al., "Protein Loop Grafting to Construct a Variant of tissue-type Plasminogen activator that Binds Platelet Integrin α <sub>lib</sub> B3*, J. Biol. Chem., No. 27						
	No. 51, pp. 30486-30490, 1995						
	Smith, G., Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface," Science, 228, pp. 1315-7, 1985  Smith et al., "Building Synthetic antibodies as Adhesive Ligands for Integrins*," J. Biol. Chem., Vol. 269, No. 52, pp. 32788-95, 1994						
	Sottrup-Jensen et al., "The α-Macroglobulin Bait region," <i>J. of Biological Chemistry</i> , V. 264, No. 27, pp. 15781-89, 1989  Stelle et al., "Bredsugs: A Chemical Approach to Targeted Drug Delivery," Directed Drug Delivery, P. Berchardt et al. Eds., pp. 247-67. Humana Press						
	Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery," <i>Directed Drug Delivery</i> , R. Borchardt et al, Eds., pp. 247-67, Humana Press, 1985						
	Stinchcomb et al., "Isolation and characterization of a yeat chromosomal replicator," Nature, Vol. 282, pp. 39-43, 1979						
	Syrigos & Epenetos, "Antibody Directed Enzyme Prodrug Therapy (ADEPT): A Review of the Experimental and Clinical Considerations," Anticancer Res., Vol. 19, pp. 605-614, 1999						
	Torchilin,V., "Drug targeting," Eur. J. Pharm. Sci., 11 Suppl. 2, pp. S81-S91, 2000						
	Travis & Salvesen, "Human Plasma Proteinase Inhibitors," Annu. Rev. Biochem., 52:655-709, 1983						
	Trouet et al., "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies," Proc. Natl. Acad. Sci. USA, Vol. 79, pp. 626-629, 1982						
	Tschumper et al., Sequence of a yeast DNA fragment containing	a chromosomal replicator and the TRP1 gene, "Gene, Vol. 10, 157-166, 1980					
Examiner		Date Considered					

PTO-1449

considered. Include copy of this form with next communication to applicant.

•			1	·				
Attorney Docket	No.: GC-714	PEV		Serial No.: 10/022,097	Pro-			
Applicant: Schelle	enberger, Volker	ان ان ا			TECEIVED			
Filing Date: Dece	mber 13, 2001	MAY 2 0 2002		Group: Unassigned	MAY 5. 2 2002			
Page 1 of 5		AIE VAL		Date of this Submission: May 1	15, 2002 Trai			
		& TRADEMARK	OTHER DOC	UMENTS	TECH CENTER 1600/2900			
Examiner's								
Initials	Author, Title, Date, Pertinent Pages, etc.							
	Umemoto et al., "Preparation and In Vitro Cytotoxicity of a Methotrexate-Anti-MM46 Monoclonal Antibody Conjugate Via An Oligopeptide Spacer," Int. J. Cancer, Vol. 43, pp. 677-684, 1989							
•	Van Solingen, et al., Fusion of Yeast Spheroplasts," J. of Bacteriology, Vol. 130, No. 2, pp. 946-947							
	Wang, et al., Éngineering the Independent Folding of the Subtilisin BPN' Pro-Domain: Correlation of Pro Domain Stability with the Rate of Subtilisin Folding," Biochemistry, Vol. 37, pp. 31-65-3171							
	Ward et al., "Retrieval of human antibodies from phage-display libraries using enzymatic cleavage," J. Immunol. Methods, Vol. 189, pp. 73-82, 1996							
	Wilman, E., "Prod	irugs In Cancer Chemotherap	oy," Biochemical So	ociety Transactions, 14, pp. 375-82 (	615th Meeting, Belfast, 1986)			
<del> </del>	Wray et al., "Use o	of a non-rigid region in T4 lyso	ozyme to design an	adaptable metal-binding site," Prote	ein Engineering, Vol. 13, No. 5, pp. 313-321, 2000			
			Frc Homology 3 Dor	main - Ligand Interactions with Alkali	ine Phosphatase Fusion Proteins," Analytical			
	Biochemistry, Vol. 247, pp. 143-151, 1997  Yuan et al., "Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size," Cancer Res., Vol. 55, pp.3752-3756, 1995							
Examiner				Date Considered				
			****					
Examiner: Initial	if reference conside	ered, whether or not citation	n is in conforman	ce with MPEP 609; draw line throu	igh citation if not in conformance and not			
considered. Incl	ude copy of this for	m with next communication	າ to applicant.	<del></del>	PTO-1449			